+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07164885

Phase IIIII Trial of Personalized Adaptive Radiotherapy Using RAPART in Adults With Locally Advanced Non-small Cell Lung Cancer

Led by Capital Medical University · Updated on 2025-12-02

911

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating Radiosensitivity-Assisted Personalized Adaptive Radiotherapy Technology RAPART in patients with locally advanced non-small cell lung cancer NSCLC that cannot be removed by surgery. This Phase IIIII randomized clinical trial aims to compare overall survival, progression-free survival, and local progression-free survival between RAPART and conventional 60 Gy radiotherapy. The study focuses on unresectable stage III NSCLC and explores how personalized radiation doses based on biomarker sensitivity may improve outcomes. The trial includes two treatment groups one receiving RAPART technology and the other receiving conventional radiotherapy with 2 Gy per fraction. RAPART combines adaptive radiotherapy ART and radiosensitivity-assisted personalized radiotherapy RAPRT over no more than 30 treatment sessions. The first stage matches conventional radiotherapy with 23 doses of 2 Gy each. After 17-19 doses, imaging is repeated to create a new adaptive plan for the second stage. RAPRT uses ERCC12 biomarkers to categorize patients into five radiosensitivity groups, each receiving a different radiation dose 74, 66, 62, 54, or 50 Gy. Participants will be monitored from randomization up to 100 months for overall survival and for three years after treatment for progression-free survival and toxic events. The study involves regular imaging and clinical assessments to track disease progression and side effects. Researchers will evaluate how personalized radiation dosing affects survival and safety compared to standard radiotherapy. The trial is sponsored by Capital Medical University and includes adults aged 18 and older with stage III unresectable NSCLC.

CONDITIONS

Brief Title

RAPART in Locally Advanced Non-small Cell Lung Cancer Patients

Research Team

F

Feng-Ming (Spring) Kong

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here